HighTower Advisors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

HighTower Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-131,900	Closed	-$4.61M	–	3995
2024 Q1	$4.61M	Hold	131,900	–	–	0.01%	1005
2023 Q4	$5.01M	Hold	131,900	–	–	0.01%	971
2023 Q3	$2.42M	Hold	131,900	–	–	﹤0.01%	1274
2023 Q2	$3.42M	Sell	131,900 -808	-0.6%	-$18.9K	0.01%	1073
2023 Q1	$2.5M	Hold	132,708	–	–	0.01%	1165
2022 Q4	$3.27M	Buy	132,708 +808	+0.6%	+$23.8K	0.01%	1022
2022 Q3	$2.37M	Buy	131,900 +121,900	+1,219%	+$2.2M	0.01%	1138
2022 Q2	$114K	Hold	10,000	–	–	﹤0.01%	2768
2022 Q1	$223K	Buy	+10,000	New	+$255K	﹤0.01%	2752

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HighTower Advisors's INBX Position: Q2 2024 in Review

HighTower Advisors sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 131,900 shares — an estimated $4.61M sold.

HighTower Advisors first reported a position in INBX in Q1 2022 and held it in 9 quarters. The position peaked at $5.01M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

HighTower Advisors reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
HighTower Advisors sold 131,900 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $4.61M.
HighTower Advisors first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
HighTower Advisors's Inhibrx, Inc. Common Stock position peaked at $5.01M in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on HighTower Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.